口服α4β7拮抗肽PTG-100的临床前开发及溃疡性结肠炎1期和2a期研究
本研究在临床前模型中表征口服α4β7拮抗肽PTG-100,并在健康志愿者中开展1期研究、在中重度活动性溃疡性结肠炎患者中开展2a期随机对照试验。2a期最初未达到主要终点,但第三方盲法内镜视频重读提示与组织学缓解相结合的临床疗效,且与低于100%外周血受体占有率相关。
要点
- PTG-100在小鼠中显示高水平的肠道相关淋巴组织靶点结合与暴露。
- 2a期最初未达主要终点,第三方盲法内镜重读提示临床疗效。
- 疗效与低于100%外周血受体占有率相关,提示局部肠道活性更重要。
核心结论
- 口服α4β7整合素拮抗剂的局部肠道活性(而非外周血完全靶点结合)对溃疡性结肠炎疗效重要。
- PTG-100在1期和2期研究中安全且耐受良好。
- 2a期数据与生物学和临床应答一致,并显示剂量反应。
研究设计与样本
- 临床前研究:体外结合实验及小鼠生物标志物与药物浓度检测。
- 1期研究:健康志愿者。
- 2a期:中重度活动性溃疡性结肠炎患者随机接受PTG-100(150、300或900 mg)或安慰剂每日一次治疗12周。
主要发现
- PTG-100强效且选择性地阻断α4β7。
- 小鼠口服给药显示肠道相关淋巴组织中高水平的靶点结合与暴露。
- 健康志愿者中血浆暴露和血液靶点结合呈剂量依赖性增加。
- 2a期最初未达到主要终点。
- 第三方盲法内镜视频重读提示与组织学缓解相结合的临床疗效,剂量与低于100%外周血受体占有率相关。
关键数值与推荐
- 2a期剂量:PTG-100 150、300或900 mg每日一次,疗程12周。
- 疗效相关条件:剂量与外周血受体占有率低于100%相关。
临床怎么用
- 口服α4β7拮抗剂治疗溃疡性结肠炎时,可关注局部肠道靶点结合而非追求外周血完全受体占有率。
- 内镜评估的盲法中央重读可能影响对疗效的判定。
局限性
- 2a期研究最初未达到主要终点。
- efficacy证据来自第三方盲法内镜视频重读的事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Oral therapies targeting the integrin α4β7 may offer unique advantages for the treatment of inflammatory bowel disease. We characterized the oral α4β7 antagonist peptide PTG-100 in preclinical models and established safety, pharmacokinetic/pharmacodynamic relationships, and efficacy in a phase 2a trial in patients with ulcerative colitis (UC). METHODS: In vitro studies measured binding properties of PTG-100. Mouse studies measured biomarkers and drug concentrations in blood and tissues. The phase 1 study involved healthy volunteers. In phase 2a, patients with moderate to severe active UC were randomized to receive PTG-100 (150, 300, or 900 mg) or placebo once daily for 12-weeks. RESULTS: PTG-100 potently and selectively blocks α4β7. Oral dosing of PTG-100 in mice showed high levels of target engagement and exposure in gut-associated lymphoid tissues. In healthy volunteers, PTG-100 showed dose-dependent increases in plasma exposure and blood target engagement. Although this phase 2a study initially did not meet the primary endpoint, a blinded reread of the endoscopy videos by a third party indicated clinical efficacy in conjunction with histologic remission at doses correlating with less than 100% receptor occupancy in peripheral blood. CONCLUSIONS: PTG-100 showed local gastrointestinal tissue target engagement and inhibition of memory T-cell trafficking in mice. It was safe and well tolerated in phase 1 and 2 studies. Phase 2a data are consistent with biological and clinical response and showed a dose response reflecting similar activities in preclinical models and healthy individuals. These data suggest that local gut activity of an oral α4β7 integrin antagonist, distinct from full target engagement in blood, are important for efficacy and the treatment of UC. (ClinicalTrials.gov, Number NCT02895100; EudraCT, Number 2016-003452-75).
引用
- Sandborn WJ, Mattheakis LC, Modi NB, et al. PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis. Gastroenterology. 2021. PMID: 34474038. doi:10.1053/j.gastro.2021.08.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。